Notable insider buying and selling activity across public companies.
Tracking and analysis of reported insider transactions, including executive and director buying or selling. Insider activity can offer insight into internal confidence, valuation perceptions, and potential inflection points.
11,898 total articles
Capital V LLC, holding a 10% stake in Viant Technology Inc., sold 37,500 shares of Class A Common Stock totaling approximately $459,389 between January 20 and January 22, 2026. Viant Technology recently reported robust third-quarter earnings surpassing analyst estimates and unveiled a programmatic advertising partnership with iHeartMedia. Analyst f…
Coreweave's Chief Development Officer, Brannin McBee, recently sold 130,345 Class A shares valued at approximately $12.5 million, according to filings from January 20, 2026. The sales were undertaken through a Rule 10b5-1 trading plan and coincided with company developments including enhanced AI platform offerings and financial adjustments. Despite…
CoreWeave's Chief Development Officer Brannin McBee sold over 34,000 shares totaling approximately $3.3 million under a structured trading plan, reflecting a complex stock position management amid significant company developments including loan amendments and AI technology integration plans. The stock has experienced substantial annual gains despit…
Abeona Therapeutics Chief Executive Officer Vishwas Seshadri executed a sale of nearly 70,000 shares for $372,267 to address tax liabilities linked to restricted stock awards. The biopharmaceutical firm also reported a better-than-expected quarterly earnings performance, while making strategic appointments and expanding its gene therapy treatment f…
Joseph Walter Vazzano, CFO of Abeona Therapeutics Inc, sold over 18,600 shares to meet tax obligations following restricted stock vesting. This insider sale follows the company’s positive third-quarter financial report and advancements in its gene therapy treatment offerings. Industry analysts present mixed price targets, reflecting ongoing operati…
Brendan M. O’Malley, Senior Vice President and Chief Legal Officer at Abeona Therapeutics Inc., recently sold 13,578 shares worth approximately $72,382. The move occurred during a period marked by the company's stronger-than-expected earnings report, leadership changes, and shifts in analyst price targets. Abeona continues to maintain a solid liqui…
Fairmount Funds Management LLC, a director entity of Cogent Biosciences, executed a major sale of 3.5 million shares at $36.40 each, totaling $127.4 million on January 22, 2026. This transaction took place while Cogent’s stock approached its 52-week peak, reflecting exceptional growth. Despite the sale, the fund retains a substantial stake, and the…
Mark N. Tompkins, holding a 10% stake in Aeluma Inc., divested approximately 104,638 shares of the company's common stock between January 20 and January 22, 2026, generating roughly $2 million in proceeds. This transaction occurred alongside the firm's Q1 FY2026 financial results, which revealed notable revenue growth but a slight miss on expected …
Fairmount Healthcare Fund II L.P. liquidated 1.75 million shares of Apogee Therapeutics common stock at $76.30 per share in January 2026, yielding approximately $133.5 million. This transaction took place near Apogee’s 52-week peak, against a backdrop of nearly doubling its stock value in the last year. Despite this strong price performance, some v…
Gerald L. Morgan, the CEO and Executive Vice Chairman of Texas Roadhouse Inc, sold 5,000 shares at $196 each on January 20, 2026, totaling $980,000. The sale took place close to the stock’s 52-week peak of $199.99, with shares stable at $191.25 currently. Texas Roadhouse maintains a robust financial stance, reflected in a 'GREAT' InvestingPro score…
Stitch Fix Chief Financial Officer David Aufderhaar sold 24,114 shares of Class A Common Stock on January 20, 2026, at $5.1264 per share, totaling $123,618. Despite the sale, Aufderhaar retains a substantial 1,251,862 shares. The company’s stock is currently slightly above the CFO’s sale price and is considered undervalued by InvestingPro’s Fair Va…
GigaCloud Technology Inc's CEO Wu Lei and related entities executed a series of share sales totaling approximately $892,140 between January 20 and 22, 2026. Despite these transactions, the company shows robust financial health, with strong quarterly earnings surpassing expectations and strategic moves including a recent acquisition. The sales were …
Kenneth Duda, President and CTO of Arista Networks, completed a substantial sale of nearly 30,000 shares and exercised stock options, amidst the company's rising share price and ongoing favorable analyst recommendations. Additional share sales by trusts linked to Duda highlight internal liquidity actions as the company prepares for its upcoming ear…
Elliot Dean Hoops, serving as General Counsel and Secretary for MP Materials Corp, finalized a stock sale valued at approximately $533,606, disposing of 7,823 shares at varied prices in late January 2026. This transaction adhered to a previously established Rule 10b5-1 trading schedule. Concurrently, MP Materials has reported important progress in …
Christopher Gibson, director at Recursion Pharmaceuticals, sold 40,000 shares of Class A Common Stock in January 2026, coinciding with a stock conversion of Class B to Class A shares. Meanwhile, the company disclosed promising interim results from its Phase 1b/2 TUPELO trial assessing the investigational drug REC-4881, showing substantial reduction…
Jonathan Zalevsky, Chief Research and Development Officer at biopharmaceutical company Nektar Therapeutics, sold 3,867 company shares worth approximately $137,935 at an average price of $35.67 on January 20, 2026. This transaction follows recent mixed results from Nektar's Phase 2b REZOLVE-AA trial for alopecia areata, which narrowly missed its pri…
Campbell Bradley L., the President and CEO of Amicus Therapeutics, completed a sale of 75,000 shares on January 20, 2026, generating approximately $1.07 million. Alongside this, he exercised options to acquire an equal number of shares. This insider activity coincides with a strong market performance for Amicus shares and the announcement of an all…
EverCommerce Inc. CEO Eric Richard Remer completed two stock sale transactions in late January 2026, liquidating approximately $171,000 in shares through a structured trading plan. The company recently announced third-quarter 2025 results reflecting slight revenue gains yet received cautious analyst reactions, highlighting a balanced risk landscape…
Jay L. Schottenstein, serving as Executive Chairman and CEO of American Eagle Outfitters (NASDAQ:AEO), executed a series of stock sales totaling nearly $26.8 million by divesting 1,049,679 shares within a three-day period. Concurrently, the company has adjusted its fourth-quarter operating income forecast upward and announced a strategic global par…
John Alexander Kelly, CFO of Precision Biosciences Inc., sold over 15,000 shares at $4.03 each on January 21, 2026, amounting to just above $61,000. Concurrently, Kelly vested a substantial number of restricted stock units the previous day. Precision Biosciences continues to make progress in its gene editing programs and financial positioning amids…
Dario Scimeca, the General Counsel and Secretary of Precision BioSciences (NASDAQ:DTIL), executed the sale of 8,854 of the company’s common shares for a total of $35,681 on January 21, 2026. This transaction comes while the stock trades slightly above the sale price and amid an InvestingPro assessment rating the shares as overvalued. Concurrently, …
Precision Biosciences Inc's Chief Research Officer, Smith J. Jefferson, recently sold over 10,000 shares of the company's stock while concurrently acquiring a larger number of shares from vested Restricted Stock Units. The company continues to move forward with key gene editing clinical trials and maintains strong liquidity after a recent capital r…
Mara Holdings CEO Frederick G. Thiel sold over 27,000 shares on January 20, 2026, netting approximately $297,000. The transaction was part of a pre-established trading plan, set against the backdrop of fluctuating cryptocurrency markets and varied analyst outlooks. Despite recent declines in Mara's stock tied to Bitcoin price weakness, the company’…
Abraham Ceesay, CEO of clinical-stage biotech firm Rapport Therapeutics, sold just over 10,900 shares valued at approximately $285,000 in two transactions under a pre-established trading plan. These dealings occur as the company expedites Phase 3 trials for its epilepsy drug RAP-219, earning favorable analyst responses and raising price targets for…
DraftKings Inc.'s Chief Legal Officer, Dodge R Stanton, recently undertook significant stock transactions involving both the sale of shares and the exercise of stock options. These actions took place against a backdrop of notable share price volatility, analyst optimism about the company’s potential profitability, and a fluctuating online sports be…
